Company Overview of VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of small molecule product candidates. It develops Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases; and VTX-2337, a small molecule TLR8 agonist to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells. The company’s products also include VTX-1463, a TLR8 agonist administered intra-nasally for the treatment of seasonal and perennial allergies; and TLR8 antagonists for autoimmune diseases, including rheumatoid arthritis. VentiRx Pharmaceutica...
1191 Second Avenue
Seattle, WA 98101
Founded in 2006
Key Executives for VentiRx Pharmaceuticals, Inc.
Vice President of Finance and Administration
Compensation as of Fiscal Year 2014.
VentiRx Pharmaceuticals, Inc. Key Developments
VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM
Jun 11 14
VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM. Venue: Washington State Convention Center, Seattle, Washington, United States.
VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM
Jun 2 14
VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Robert M. Hershberg, Co-Founder, Chief Executive Officer and Director.
VentiRx Pharmaceuticals, Inc. Announces the Completion of Patient Enrollment in Randomized, Placebo-Controlled Phase 2 Trial of VTX-2337
Apr 17 14
VentiRx Pharmaceuticals, Inc. announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. VTX-2337 is a novel, investigational small molecule that targets Toll-like receptor 8 (TLR8). PLD is the standard of care for the treatment of platinum-resistant ovarian cancer and encouraging data have been reported with PLD and VTX-2337 in a recently completed Phase 1b study (GOG-9925, NCT01294293). The Phase 2 GOG-3003 study has reached its target enrollment with more than 290 patients randomized at over 85 institutions throughout North America. The study is being performed in collaboration with the Gynecologic Oncology Group partners program. Women were randomized to receive PLD plus VTX-2337 or PLD plus placebo. The primary endpoint of the trial is overall survival. GOG-3003 is one of two Phase 2 clinical trials of VTX-2337 currently underway. The second trial, called Active8, is a company-sponsored, randomized, Phase 2 placebo-controlled trial in patients with locally advanced and metastatic squamous cell carcinoma of the head and neck. The study is evaluating VTX-2337 in combination with cetuximab and chemotherapy vs. cetuximab and chemotherapy alone. Progression-free survival is the primary endpoint.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|